Thomas Simmerer takes over sales at Carl Zeiss Meditec
Succeeds Ulrich Krauss as member of the management board with responsibility for sales
‘I am looking forward to my new responsibilities and will maintain and expand the successful sales and service structure at Carl Zeiss Meditec in the respective markets,’ said Simmerer.
Simmerer has extensive experience in medical technology. He was in charge of the Microsurgery strategic business unit in Oberkochen from October 2008. Before joining the medical wing of Carl Zeiss, the mechanical engineer led the top-performing business unit, among others, of Dräger Medical in Lübeck from 1996 to 2008. Prior to this, he was responsible for different sales areas at Heraeus in Hanau.
You may also like
Pharma 5.0
ZEISS and Concept Life Sciences partner to advance automated workflows and AI-powered image analysis in spatial biology
The collaboration focusses on high-throughput imaging, AI-driven data analysis and streamlined integration into lab systems, aiming to improve efficiency and data quality for areas such as drug discovery and cancer research
Research & Development
Medicines Discovery Catapult and ZEISS set sights on advancing microscopy in drug discovery
Medicines Discovery Catapult (MDC) and ZEISS have joined forces to improve drug discovery and early development of complex medicines by harnessing the power of advanced microscopy solutions
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Drug Delivery
Stevanato Group launches Deora pen injector platform targeting GLP-1 and incretin therapies
The fixed-dose, multi-use pull-push device accommodates volumes up to 0.75 mL, offering pharma partners a scalable, error-reducing delivery solution for diabetes and weight management programmes